Pavan, Fernando Rogério [UNESP]Poelhsitz, Gustavo V.Barbosa, Marilia I. F.Leite, Sergio R. A. [UNESP]Batista, Alzir A.Ellena, JavierSato, Leticia S. [UNESP]Franzblau, Scott G.Moreno, VirtudesGambino, DinorahLeite, Clarice Queico Fujimura [UNESP]2014-05-202014-05-202011-10-01European Journal of Medicinal Chemistry. Paris: Elsevier France-editions Scientifiques Medicales Elsevier, v. 46, n. 10, p. 5099-5107, 2011.0223-5234http://hdl.handle.net/11449/7486This paper describes the synthesis and characterization of four new ruthenium complexes containing 1,4 bis(diphenylphosphino)butane (dppb), 2-pyridinecarboxylic acid anion (pic) and the diimines [(2,2'-bipyridine (bipy), 4,4'-dimethyl-2,2'-bipyridine (Me-bipy), 4,4'-dichloro-2,2'-bipyridine (Cl-bipy) and 1,10-phenanthroline (phen) as ligands, with formulae [Ru(pic)(dppb)(bipy)]PF6 (SCAR01), [Ru(pic)(dppb) (Me-bipy)]PF6 (SCAR02), [Ru(Pic)(dPPb)(Cl-bipy]PF6 (SCAR03) and [Ru(pic)(dppb)(phen)]PF6 (SCAR04). Additionally, the in vitro anti-Mycobacterium tuberculosis (MTB) activity, cytotoxicity and activity against in vitro infection of these complexes and two more complexes, cis-[Ru(pic)(dppe)(2)]PF6(SCAR05) and cis-[RuCl2(dppb)(bipy)] (SCAR06), and their free ligands are described and discussed. All compounds showed excellent MIC against MTB, low cytotoxicity and a selectivity index higher than 10. Also, all compounds showed significant intracellular inhibition and the compound SCAR05 showed a better activity than rifampin and SQ109. This is the first report of activity against in vitro infection of ruthenium compounds. (C) 2011 Elsevier Masson SAS. All rights reserved.5099-5107engMycobacterium tuberculosisDrug resistanceRutheniumPhosphine/diimine/picolinateArtigo10.1016/j.ejmech.2011.08.023WOS:000296041600033Acesso restrito2114570774349859